Bionano Genomics, Inc. 8-K

What Happened

• Bionano Genomics (BNGO) filed an 8-K reporting that on May 5, 2026 its President and Chief Executive Officer, R. Erik Holmlin, Ph.D., was terminated effective immediately and resigned from the Board. The company says Dr. Holmlin is entitled to severance under his employment agreement, subject to a release and other conditions, and is expected to enter a consulting agreement to assist with transition.
• The Board appointed Chairman Albert A. Luderer, Ph.D., as Interim Chief Executive Officer (effective May 5, 2026). Dr. Luderer will also serve as the company’s interim principal financial officer and will remain Chairman of the Board while stepping down from three Board committees. The company plans to begin a search for a permanent CEO.

Key Details

• Effective date of change: May 5, 2026 (8-K filed May 6, 2026).
• Interim CEO pay package (Offer Letter dated May 6, 2026): $600,000 annual base salary; 2026 annualized incentive opportunity up to $400,000 (pro rata for time served); $4,000 per month housing and travel stipend.
• Dr. Holmlin resigned from the Board and any Board committees; he may perform consulting services under a separate agreement.
• The Board also named Christopher J. Twomey as Lead Independent Director and added him to the Compensation Committee. A press release was attached as Exhibit 99.1 to the 8-K.

Why It Matters

• Executive leadership changes can affect strategy, operations and investor confidence. The appointment of an experienced interim CEO who will also serve as interim principal financial officer is a temporary governance shift while the company searches for a permanent CEO.
• There may be near-term costs (severance, interim CEO compensation) and further disclosures to watch for, including the final severance/release terms, any consulting agreement with Dr. Holmlin, and the full Offer Letter for Dr. Luderer when filed with the SEC. Investors should monitor subsequent filings and company communications for updates.